This measure captures the proportion of ischemic stroke patients prescribed antithrombotic therapy at hospital discharge.
This measure is a part of a set of eight nationally implemented measures that address stroke care (STK-1: Venous Thromboembolism (VTE) Prophylaxis, STK-3: Anticoagulation Therapy for Atrial Fibrillation/Flutter, STK-4: Thrombolytic Therapy,STK-5: Antithrombotic Therapy By End of Hospital Day 2, STK-6 Discharged on Statin Medication, STK-8: Stroke Education, and STK-10: Assessed for Rehabilitation) that are used in The Joint Commission’s hospital accreditation and Disease-Specific Care certification programs.
- Measure TypeElectronic Clinical Quality Measure (eCQM)Care SettingNumerator
Ischemic stroke patients prescribed antithrombotic therapy at hospital
dischargeDenominatorIschemic stroke patients
Exclusions• Less than 18 years of age
• Length of Stay > 120 days
• Comfort measures only documented
• Enrolled in clinical trials related to stroke
• Admitted for elective carotid intervention
• Discharged to another hospital
• Left against medical advice
• Expired
• Discharged to home for hospice care
• Discharged to a health care facility for hospice care
• Documented reason for not prescribing antithrombotic therapy at dischargeTesting Data Sources
- Measure StructureClinical Condition Topic AreaNon Condition SpecificTarget PopulationMeasure Selection AttributesNational Quality Strategy PrioritiesEffective Communication and Care Coordination
- Risk Adjustment
- Current or planned use(s)
- Most Recent Endorsement ActivityEndorsed with Reserve Status Neurology Project 2015-2016Initial EndorsementEndorsement StatusLast Updated
- StewardSteward Organization EmailSteward Organization Copyright
No royalty or use fee is required for copying or reprinting this manual, but the following are required as a condition of usage: 1) disclosure that the Specifications Manual is periodically updated, and that the version being copied or reprinted may not be up-to-date when used unless the copier or printer has verified the version to be up-to-date and affirms that, and 2) users participating in Joint Commission accreditation, including ORYX® vendors, are required to update their software and associated documentation based on the published manual production timelines.